Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup—A Multicenter Study
Authors: Priora Marta , Becciolini Andrea , Celletti Eleonora , Di Penta Myriam , Lo Gullo Alberto , Paroli Marino , Bravi Elena , Andracco Romina , Nucera Valeria , Ometto Francesca , Lumetti Federica , Farina Antonella , Del Medico Patrizia , Colina Matteo , Ravagnani Viviana , Scolieri Palma , Larosa Maddalena , Visalli Elisa , Addimanda Olga , Vitetta Rosetta , Volpe Alessandro , Bezzi Alessandra , Girelli Francesco , Molica Colella Aldo Biagio , Caccavale Rosalba , Di Donato Eleonora , Adorni Giuditta , Santilli Daniele , Lucchini Gianluca , Arrigoni Eugenio , Sabatini Emanuela , Platè Ilaria , Mansueto Natalia , Ianniello Aurora , Fusaro Enrico , Ditto Maria Chiara , Bruzzese Vincenzo , Camellino Dario , Bianchi Gerolamo , Serale Francesca , Foti Rosario , Amato Giorgio , De Lucia Francesco , Bosco Ylenia Dal , Foti Roberta , Reta Massimo , Fiorenza Alessia , Rovera Guido , Marchetta Antonio , Focherini Maria Cristina , Mascella Fabio , Bernardi Simone , Sandri Gilda , Giuggioli Dilia , Salvarani Carlo , Franchina Veronica , Molica Colella Francesco , Ferrero Giulio , Ariani Alarico , Parisi Simone 
Published: December 2024

Background and Objectives: The treatment landscape for Rheumatoid Arthritis (RA) has evolved significantly with the introduction of Janus kinase inhibitors (JAKi), such as Tofacitinib (TOFA), which offer a new therapeutic option for patients who have failed or are intolerant to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Safety concerns, particularly related to cardiovascular and cancer risks, prompted a need for additional investigation in real-world clinical settings. This study aimed to evaluate the long-term effectiveness and predictors of response to TOFA in two subpopulations of RA patients, categorized by differing cardiovascular risk profiles. Materials and Methods: This was a retrospective, multicenter observational study conducted as part of the BIRRA project, involving 23 Italian rheumatological referral centers. A total of 213 patients diagnosed with RA and treated with TOFA were included, with data collected on baseline demographics, clinical history, disease activity, and comorbidities. Patients were divided into high-risk and low-risk cardiovascular groups based on age (≥65 years) and the presence of at least one cardiovascular risk factor. Disease activity was assessed at baseline, 6 months, and 12 months using DAS28-ESR and DAS28-CRP. Treatment response was evaluated using intention-to-treat (ITT) and per-protocol (PP) approaches. Predictors of low disease activity (LDA) and remission were assessed through logistic regression, and clustering analyses were used to identify subgroups of patients with different therapeutic responses. Results: The study included 213 patients, with 129 classified as high-risk. For the overall cohort, patients achieving LDA and remission at 6 months were 20% and 12%, respectively, for the ITT analysis, and 29% and 14% for the PP analysis. At 12 months, 26% of patients reached LDA, and 17% achieved remission according to ITT, while for the PP analysis, these rates were 30% and 19%, respectively. No significant differences in remission or LDA rates were observed between the high-risk and low-risk groups. In the high-risk subgroup, 17% of patients reached LDA and 9% achieved remission at 6 months (ITT analysis), while these rates increased to 22% and 13%, respectively, in the PP analysis. At 12 months, 22% achieved LDA and 13% achieved remission in the ITT analysis, while 28% and 17% did so in the PP analysis. The reduction in DAS28-ESR and DAS28-CRP scores was significant (p < 0.001) across all time points for both high-risk and low-risk patients. Logistic regression analyses revealed that none of the baseline characteristics—including age, sex, comorbidities, rheumatoid factor, anti-citrullinated protein antibody (ACPA) positivity, initial disease severity, or treatment history—were significant predictors of remission or LDA at 6 or 12 months. The clustering analysis suggested that older patients, particularly those with worse baseline DAS28 scores, tended to show a less favorable response to treatment, potentially indicating impacts of age-related factors such as immunosenescence on therapeutic outcomes. Conclusions: Tofacitinib demonstrated similar effectiveness in both high- and low-risk cardiovascular subgroups of RA patients, with significant reductions in disease activity observed at both 6 and 12 months. Despite safety concerns related to cardiovascular risk, TOFA remained an effective treatment option across patient subgroups, with no significant differences in remission or LDA rates based on cardiovascular risk profiles. Age appeared to negatively impact treatment response, highlighting the role of immunosenescence in RA management. These findings support the use of TOFA as a personalized therapeutic option for RA, emphasizing the need for careful evaluation of cardiovascular and age-related risks in clinical decision-making.